KYORIN Pharmaceutical (4569) · TargetWorsened
Stage 3 Targets: Revenue CAGR of at Least 5% and Operating Margin before R&D Expenses of at Least 20%
First written in FY2020. 1 of 2 entries say "Worsened", first in FY2023. Latest entry: FY2023.
2entries
4years
0from disclosures
How it moved
Same theme, other companies
Setting and achieving performance targets under the medium-term management planA theme 790 companies write about · 75 as a headwind · 1061 as a tailwind
The whole theme swung hardest in 2021: 17 of 77 companies on the "Worse" side.
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 133 companies compared. The sentences above are computed from all 133.Comparing 200 of the theme's 1181 threads.Full recordFilings, disclosures and news, newest first
- FY2023WorsenedAnnual report
「Against the numerical targets for the medium-term management plan HOPE100—Stage 3—(fiscal 2020 to fiscal 2023), namely a consolidated revenue CAGR of at least 5% and operating profit before R&D expenses of at least 20% of revenue, actual results were a consolidated revenue CAGR of 1.0% and operating profit before R&D expenses of 14.2% of revenue.」
Against the Stage 3 numerical targets, actual results were a revenue CAGR of 1.0% and operating profit before R&D expenses of 14.2% of revenue, below the targets of at least 5% and at least 20%. - FY2020First statedAnnual report
「Growth: revenue CAGR of at least 5%. Profitability: operating profit before R&D expenses (operating profit plus R&D expenses) as a percentage of revenue of at least 20%.」
Stage 3 set consolidated targets of a revenue CAGR of at least 5% and operating profit before R&D expenses as a percentage of revenue of at least 20%.